Quantum BioPharma Ltd. (NASDAQ: QNTM) has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for Lucid-MS, allowing the company to proceed with a randomized, double-blind, placebo-controlled Phase 2 clinical trial in multiple sclerosis (MS). This regulatory milestone represents a critical step forward for a drug candidate that takes a novel approach to treating MS by targeting the underlying mechanism of demyelination rather than suppressing the immune system.
Lucid-MS is a patented, first-in-class, non-covalent inhibitor of peptidyl arginine deiminase 2 (PAD2). In preclinical models, it has been shown to prevent and reverse myelin degradation, the central pathological process in MS. Current MS therapies primarily modulate or suppress the immune system to reduce relapses, but they do not directly repair or protect myelin. By inhibiting PAD2, Lucid-MS aims to address demyelination directly, which could potentially slow or reverse disease progression and offer benefits to patients who do not respond adequately to existing treatments.
The FDA's acceptance of the IND means Quantum BioPharma can now initiate the Phase 2 trial, which will evaluate the safety and efficacy of Lucid-MS in patients with MS. The trial design—randomized, double-blind, and placebo-controlled—is the gold standard for clinical research, providing robust data on whether the drug works and how it compares to placebo. Success in this phase would bring Lucid-MS one step closer to regulatory approval and commercialization.
In addition to the clinical advancement, Quantum BioPharma is collaborating with Massachusetts General Hospital and Harvard Medical School on research involving the [¹⁸F]3F4AP PET imaging tracer. This tracer is being evaluated as a method to visualize and measure demyelination in the brain and spinal cord. If validated, this imaging tool could become a valuable biomarker for diagnosing MS, monitoring disease progression, and assessing the effectiveness of therapies like Lucid-MS in clinical trials and eventually in clinical practice.
The announcement places Quantum BioPharma alongside other companies making strides in areas of unmet medical need. Novartis AG (NYSE: NVS) recently received FDA approval for Pluvicto® in combination with an androgen receptor pathway inhibitor for certain patients with metastatic hormone-sensitive prostate cancer. Merck & Co. Inc. (NYSE: MRK) had its supplemental Biologics License Application for ENFLONSIA™ accepted by the FDA to expand its indication for certain children at increased risk for severe respiratory syncytial virus disease. TG Therapeutics Inc. (NASDAQ: TGTX) initiated a Phase 2 trial of BRIUMVI® in adults with treatment-resistant schizophrenia. Bristol-Myers Squibb Company (NYSE: BMY) reported positive Phase 2 results from the registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel in heavily pretreated relapsed and refractory multiple myeloma.
For Quantum BioPharma, the FDA clearance for Lucid-MS is a significant de-risking event that could attract investor attention and validate its research platform. The company’s pipeline also includes UNBUZZD™, an over-the-counter product spun out to Unbuzzd Wellness Inc., in which Quantum retains a 19.84% ownership stake as of March 31, 2026, and royalty rights. However, the primary near-term value driver remains Lucid-MS, which addresses a large and growing MS market with a differentiated mechanism. If the Phase 2 trial yields positive results, Quantum BioPharma could become a notable player in the neuroinflammatory disease space.
To view the full press release, visit https://ibn.fm/lCey9. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
